{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T03:22:19Z","timestamp":1785468139455,"version":"3.56.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2003,2,1]],"date-time":"2003-02-01T00:00:00Z","timestamp":1044057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2003,2,1]],"date-time":"2003-02-01T00:00:00Z","timestamp":1044057600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hum Hypertens"],"published-print":{"date-parts":[[2003,2,1]]},"DOI":"10.1038\/sj.jhh.1001511","type":"journal-article","created":{"date-parts":[[2003,2,6]],"date-time":"2003-02-06T15:41:23Z","timestamp":1044546083000},"page":"81-86","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":106,"title":["Better blood pressure control: how to combine drugs"],"prefix":"10.1038","volume":"17","author":[{"given":"M J","family":"Brown","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J K","family":"Cruickshank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A F","family":"Dominiczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G A","family":"MacGregor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N R","family":"Poulter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G I","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Thom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2003,2,6]]},"reference":[{"key":"BF1001511_CR1","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1126\/science.274.5288.740","volume":"274","author":"CJL Murray","year":"1998","unstructured":"Murray CJL, Lopez AD . Evidence-based health policy\u2014lessons from the global burden of disease study. Science 1998; 274: 740\u2013743.","journal-title":"Science"},{"key":"BF1001511_CR2","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/0140-6736(90)90878-9","volume":"335","author":"S MacMahon","year":"1990","unstructured":"MacMahon S et al. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765\u2013774.","journal-title":"Lancet"},{"key":"BF1001511_CR3","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1016\/S0140-6736(00)03307-9","volume":"356","author":"B Neal","year":"2000","unstructured":"Neal B, MacMahon S, Chapman N . Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 2000; 356: 1955\u20131964.","journal-title":"Lancet"},{"key":"BF1001511_CR4","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1136\/bmj.319.7210.630","volume":"319","author":"LE Ramsay","year":"1999","unstructured":"Ramsay LE et al. British Hypertension Society guidelines for hypertension management 1999. BMJ 1999; 319: 630\u2013635.","journal-title":"BMJ"},{"key":"BF1001511_CR5","first-page":"151","volume":"17","author":"JP Chalmers","year":"1999","unstructured":"Chalmers JP et al. World Health Organization\u2014International Society of Hypertension Guidelines for the management of hypertension. J Hypertens 1999; 17: 151\u2013185.","journal-title":"J Hypertens"},{"key":"BF1001511_CR6","doi-asserted-by":"crossref","unstructured":"The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997; 157: 2413\u20132446.","DOI":"10.1001\/archinte.157.21.2413"},{"key":"BF1001511_CR7","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1161\/hyp.38.4.827","volume":"38","author":"P Primatesta","year":"2001","unstructured":"Primatesta P, Brookes M, Poulter NK . Improved hypertension management and control: results from the health survey for England 1998. Hypertension 2001; 38: 827\u2013832.","journal-title":"Hypertension"},{"key":"BF1001511_CR8","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1097\/00004872-199816060-00005","volume":"16","author":"HM Colhoun","year":"1998","unstructured":"Colhoun HM, Dong W, Poulter NR . Blood pressure screening, management and control in England: results from the health survey for England 1994. J Hypertens 1998; 16: 747\u2013752.","journal-title":"J Hypertens"},{"key":"BF1001511_CR9","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1136\/bmj.314.7076.272","volume":"314","author":"X Du","year":"1997","unstructured":"Du X et al. Case\u2013control study of stroke and the quality of hypertension control in north west England. BMJ 1997; 314: 272\u2013276.","journal-title":"BMJ"},{"key":"BF1001511_CR10","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","volume":"351","author":"L Hansson","year":"1998","unstructured":"Hansson L, Zanchetti A . Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755\u20131762.","journal-title":"Lancet"},{"issue":"7160","key":"BF1001511_CR11","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1136\/bmj.317.7160.703","volume":"317","author":"UK Prospective Diabetes Study Group","year":"1998","unstructured":"UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703\u2013713.","journal-title":"BMJ"},{"key":"BF1001511_CR12","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","volume":"359","author":"B Dahlof","year":"2002","unstructured":"Dahlof B et al. The Losartan intervention for endpoint reduction in hypertension study. Lancet 2002; 359: 995\u20131003.","journal-title":"Lancet"},{"key":"BF1001511_CR13","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/S0140-6736(00)02527-7","volume":"356","author":"MJ Brown","year":"2000","unstructured":"Brown MJ et al. Morbidity and mortality in patients randomised to double-blind treatment with once-daily calcium channel blockade or diuretic in the International Nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356: 366\u2013342.","journal-title":"Lancet"},{"key":"BF1001511_CR14","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.3109\/10641969909061028","volume":"21","author":"J Chalmers","year":"1999","unstructured":"Chalmers J et al. 1999 World Health Organization\u2014International Society of Hypertension Guidelines for the management of hypertension. Guidelines sub-committee. Clin Exp Hypertens 1999; 21: 1009\u20131060.","journal-title":"Clin Exp Hypertens"},{"key":"BF1001511_CR15","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/0002-9149(75)90168-X","volume":"36","author":"FR Buhler","year":"1975","unstructured":"Buhler FR et al. Antihypertensive beta blocking action as related to renin and age: a pharmacologic tool to identify pathogenetic mechanisms in essential hypertension. Am J Cardiol 1975; 36: 653\u2013669.","journal-title":"Am J Cardiol"},{"key":"BF1001511_CR16","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1016\/S0140-6736(98)07614-4","volume":"353","author":"JE Dickerson","year":"1999","unstructured":"Dickerson JE et al. Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet 1999; 353: 2008\u20132013.","journal-title":"Lancet"},{"key":"BF1001511_CR17","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1097\/00004872-200204000-00037","volume":"20","author":"A Deary","year":"2002","unstructured":"Deary A et al. Double-blind, placebo-controlled crossover comparison of five classes of antihypertensive drugs. Hyperten 2002; 20: 771\u2013777.","journal-title":"Hyperten"},{"key":"BF1001511_CR18","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1056\/NEJM199304013281303","volume":"328","author":"BJ Materson","year":"1993","unstructured":"Materson BJ et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med 1993; 328: 914\u2013921.","journal-title":"N Engl J Med"},{"key":"BF1001511_CR19","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1210\/jcem-43-2-446","volume":"43","author":"GP Guthrie Jr","year":"1976","unstructured":"Guthrie Jr GP et al. Dissociation of plasma renin activity and aldosterone in essential hypertension. J Clin Endocrinol Metab 1976; 43: 446\u2013448.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF1001511_CR20","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1136\/bmj.315.7101.154","volume":"315","author":"T Philipp","year":"1997","unstructured":"Philipp T et al. Randomised, double blind, multicentre comparison of hydrochlorothiazide, atenolol, nitren-dipine, and enalapril in antihypertensive treatment: results of the HANE study. BMJ 1997; 315: 154\u2013159.","journal-title":"BMJ"},{"key":"BF1001511_CR21","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/sj.jhh.1000790","volume":"13","author":"G MacGregor","year":"1999","unstructured":"MacGregor G . The St George's \u2018Star\u2019 and Imploding Diamond'. J Hum Hypertens 1999; 13: 353\u2013354.","journal-title":"J Hum Hypertens"},{"key":"BF1001511_CR22","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/sj.jhh.1000688","volume":"12","author":"GY Lip","year":"1998","unstructured":"Lip GY, Beevers M, Beevers DG . The \u2018Birmingham Hypertension Square\u2019 for the optimum choice of add-in drugs in the management of resistant hypertension. J Hum Hypertens 1998; 12: 761\u2013763.","journal-title":"J Hum Hypertens"},{"key":"BF1001511_CR23","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1097\/00004872-200106000-00020","volume":"19","author":"PS Sever","year":"2001","unstructured":"Sever PS et al. Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. ASCOT investigators. J Hypertens 2001; 19: 1139\u20131147.","journal-title":"J Hypertens"},{"key":"BF1001511_CR24","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/0002-8703(94)90749-8","volume":"128","author":"L Lind","year":"1994","unstructured":"Lind L, Pollare T, Berne C, Lithell H . Long-term metabolic effects of antihypertensive drugs. Am Heart J 1994; 128: 1177\u20131183.","journal-title":"Am Heart J"},{"key":"BF1001511_CR25","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1111\/j.1440-1681.1994.tb02519.x","volume":"21","author":"RD Gordon","year":"1994","unstructured":"Gordon RD et al. High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol. 1994; 21: 315\u2013318.","journal-title":"Clin Exp Pharmacol Physiol."},{"key":"BF1001511_CR26","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0140-6736(05)74868-6","volume":"353","author":"PO Lim","year":"1999","unstructured":"Lim PO et al. Potentially high prevalence of primary aldosteronism in a primary-care population. Lancet 1999; 353: 40.","journal-title":"Lancet"},{"key":"BF1001511_CR27","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/sj.jhh.1000426","volume":"11","author":"P Marques-Vidal","year":"1997","unstructured":"Marques-Vidal P Tuomilehto J . Hypertension awareness, treatment and control in the community: is the \u2018rule of halves\u2019 still valid? J Hum Hypertens 1997; 11: 213\u2013220.","journal-title":"J Hum Hypertens"},{"key":"BF1001511_CR28","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1001\/archinte.1996.00440160081011","volume":"156","author":"M Epstein","year":"1996","unstructured":"Epstein M, Bakris G . Newer approaches to antihypertensive therapy. Use of fixed-dose combination therapy. Arch Intern Med 1996; 156: 1969\u20131978.","journal-title":"Arch Intern Med"},{"key":"BF1001511_CR29","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1056\/NEJM200001203420301","volume":"342","author":"S Yusuf","year":"2000","unstructured":"Yusuf S et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145\u2013153.","journal-title":"N Engl J Med"},{"key":"BF1001511_CR30","doi-asserted-by":"publisher","first-page":"142","DOI":"10.3317\/jraas.2000.017","volume":"1","author":"B Williams","year":"2000","unstructured":"Williams B . The renin angiotensin system and cardiovascular disease: hope or hype? J Renin Angiotensin Aldosterone Syst 2000; 1: 142\u2013146.","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"BF1001511_CR31","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1016\/S0140-6736(01)07186-0","volume":"358","author":"P Sleight","year":"2001","unstructured":"Sleight P et al. Blood-pressure reduction and cardiovascular risk in HOPE study. Lancet 2001; 358: 2130\u20132131.","journal-title":"Lancet"},{"key":"BF1001511_CR32","doi-asserted-by":"publisher","first-page":"28e","DOI":"10.1161\/hy1101.099502","volume":"38","author":"P Svensson","year":"2001","unstructured":"Svensson P et al. Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE substudy. Hypertension 2001; 38: 28e\u201332.","journal-title":"Hypertension"},{"key":"BF1001511_CR33","doi-asserted-by":"crossref","unstructured":"Progress Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033\u20131041.","DOI":"10.1016\/S0140-6736(01)06178-5"}],"container-title":["Journal of Human Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/1001511.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1001511","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1001511.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T20:23:22Z","timestamp":1647548602000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/1001511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,2,1]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2003,2,1]]}},"alternative-id":["BF1001511"],"URL":"https:\/\/doi.org\/10.1038\/sj.jhh.1001511","relation":{},"ISSN":["0950-9240","1476-5527"],"issn-type":[{"value":"0950-9240","type":"print"},{"value":"1476-5527","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,2,1]]},"assertion":[{"value":"16 October 2002","order":1,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2002","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2003","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}